Patient Characteristics
| Characteristic | Value |
| Median age (y) | 54 (range, 42–81) |
| Sex | |
| Male | 15 (47%) |
| Female | 17 (53%) |
| EGFR mutation status | |
| EGFR mutation | 2 (6%) |
| No EGFR mutation | 30 (94%) |
| TNM stage (seventh edition) | |
| IIIB | 1 (4%) |
| IV | 31 (96%) |
| Smoking status | |
| Current smoker | 15 (47%) |
| Former smoker | 17 (53%) |
| Previous malignancy | |
| No | 6 (19%) |
| Yes | 26 (81%) |
| CPB treatment cycles | |
| 4 | 6 (19%) |
| 4 | 26 (81%) |
| Bevacizumab maintenance cycles | |
| 0 | 6 (19%) |
| ≥1 | 26 (81%) |
| Bevacizumab and erlotinib maintenance cycles | |
| 0 | 11 (34%) |
| ≥1 | 21 (66%) |